Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints

• Published in: Alzheimer's & dementia : translational research & clinical interventions 2022, Vol.8 (1), p.e12361-n/a
• Main Authors: Petersen, Ronald C., Graf, Ana, Carrillo, Maria C., Weber, Christopher J.
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Animal cognition; Biomarkers; Clinical trials; Dementia; Monoclonal antibodies; Neurodegeneration; Observational studies; Pathophysiology
• ISSN: 2352-8737; 2352-8737
• DOI: 10.1002/trc2.12361

The meeting continued with representatives from active, observational studies sharing how biomarker and clinical data contribute to our understanding of amyloid beta, tau, and other pathologies, and subject matter experts who presented modeling data to advance AD treatment strategies. [...]biomarker changes in amyloid beta are reasonably likely to predict changes in clinical outcome measures and should be considered meaningful to all patients who may potentially benefit from these treatments. There is much work to be done, and the scientific community needs to stay focused on defining those tools most appropriate to capture these changes, the populations best suited to enroll in clinical trials, and defining our expectations of what changes can be expected over a particular interval of time. CONFLICTS OF INTEREST R.P. is a full-time employee of Mayo Foundation for Education and Research and a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc. (DSMB), and Eisai, Inc. A.G. is a full-time employee of NovartisPharma AG. M.C.C., C.J.W. are full-time employees of the Alzheimer's Association.